Search Medical Condition
Please enter condition
Please choose location from dropdown

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (116) clinical trials

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian Primary Peritoneal or Fallopian Tube Cancer

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of the autologous NY-ESO-1 redirected T cell therapy in combination with decitabine and low-dose IL-2 in patients with treatment refractory or recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma. SECONDARY OBJECTIVES: I. To evaluate the persistence of genetically modified cells ...


A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Epithelial gynecologic malignancies are tumors of mllerian origin, which include ovarian, endometrial, fallopian tube, and primary peritoneal cancers, and account for >70,000 new diagnoses and >22,000 deaths per year in the United States alone. Treatment typically consists of a thorough cytoreductive and staging surgery in combination with platinum/taxane chemotherapy. Newer ...

Phase N/A

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

The primary objective of this study is to compare overall survival (OS) in patients with platinum-sensitive recurrent ovarian cancer with a positive SCR score randomized to secondary cytoreductive surgery followed by chemotherapy versus chemotherapy alone.


Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

OBJECTIVES: Compare the efficacy and safety in patients with FIGO (2014) stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer, or peritoneal carcinoma treated with neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery. OUTLINE: This is a randomized phase III multicenter study. Patients will receive upfront maximal ...


Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

The primary objective of this study is as follows: To assess the activity of ixabepilone with bevacizumab compared to ixabepilone alone in patients with recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. We will assess this by comparing the ixabepilone +bevacizumab (experimental) arm to the ...


Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.


Pembrolizumab Paclitaxel and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

This is a single arm, open-label, phase II study to assess pathologic objective response rate (complete response + partial response) in patients treated with pembrolizumab, paclitaxel and carboplatin for advanced stage III or IV Ovarian, Fallopian Tube, or Peritoneal Carcinoma (EOC). Eligible patients will undergo tissue biopsies to confirm diagnosis, ...


Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer - REDIRECT

Part 1: Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join the study. Up to 9 participants will be enrolled in Part 1 of the study, and up to 112 participants ...


Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian Primary Peritoneal Fallopian Tube Endometrial or Triple Negative Breast Cancer

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of gemcitabine hydrochloride (gemcitabine) when given in combination with mirvetuximab soravtansine (IMGN853) to patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, endometrial cancer, or triple negative breast cancer (TNBC). SECONDARY OBJECTIVES: I. To ...


Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients With Ovarian Fallopian Tube or Primary Peritoneal Cancer Receiving Bevacizumab

PRIMARY OBJECTIVES: I. To evaluate whether those patients with an increase in perfusion computed tomography (CT) tumor blood flow (BF) from T0 to T1 demonstrate poorer progression-free survival (PFS) compared to those patients with a decrease in BF from T0 to T1, among platinum-resistant, recurrent ovarian cancer patients treated with ...